• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
Cigna Ventures | Health Care Venture Capital

Cigna Ventures | Health Care Venture Capital

  • Strategy
  • Partners
  • Team
  • News
  • Contact

Heart Health Innovator Cleerly Closes Series C Funding Round with $192 Million

July 25, 2022

Cleerly, the company creating a new standard of care for heart disease, announced that it has closed a Series C financing round of $192 million. The oversubscribed funding round was led by funds and accounts advised by T. Rowe Price Associates, Inc. and T. Rowe Price Investment Management, Inc., and Fidelity Management and Research Company. Cleerly’s existing investors participated in the financing and include Vensana Capital, LRVHealth, New Leaf Ventures, Cigna Ventures and DigiTx Partners.

SEE FULL ARTICLE

Filed Under: News

Primary Sidebar

Categories

  • News
  • Partnership Activity

More news

  • Monogram Health’s In-Home Services Now Available to More Older Adults Living with Chronic Kidney Conditions February 7, 2023
  • NOCD Completes Additional Funding in its Quest to End the OCD Crisis January 31, 2023
  • Monogram Health Closes $375M Growth Capital Raise to Support Continued Expansion of Innovative In-Home Kidney and Polychronic Care Model January 13, 2023
  • Valera Health Announces $45 Million Growth Equity Financing to Increase Access to Evidence-based Mental Health Services for High Acuity Patients October 31, 2022
  • Zerigo Health Announces Release of Eczema Solution September 15, 2022
  • Alma Raises $130M in Series D Funding led by Thoma Bravo to Advance its Mission to Simplify Access to High Quality, Affordable Mental Health Care August 25, 2022
  • InterWell Health, Cricket Health, and Fresenius Health Partners Complete Three-Way Merger, Creating Premier, Value-based Kidney Care Provider August 25, 2022

Footer

  • Strategy
  • Partners
  • Team
  • News
  • Contact

By contacting Cigna Ventures through this website, you agree and acknowledge that information you submit will not be considered or treated as confidential or proprietary unless and until a separate agreement is signed, and that Cigna Ventures and its affiliates are under no obligation to review your submission or to enter into any agreement, investment or transaction associated with the submission. In no event will Cigna Ventures or any of its affiliates be limited in, or restricted from, the pursuit of any opportunities, either alone or with third parties.

The information contained herein does not constitute a distribution, an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction in which such distribution or offer is not authorized. In particular, the information herein is not for distribution and does not constitute an offer to sell or the solicitation of any offer to buy any securities in the United States (U.S.) or for the benefit of any U.S. person (being residents of the United States. or partnerships or corporations organized under the laws of the United States), nor in any other country.

The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc.

Privacy Policy | Terms of Use | Accessibility

© 2023 Cigna. All rights reserved

This site is protected by reCAPTCHA and the Google. Privacy Policy and Terms of Service apply.